<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821442</url>
  </required_header>
  <id_info>
    <org_study_id>H2015:282</org_study_id>
    <nct_id>NCT02821442</nct_id>
  </id_info>
  <brief_title>&quot;Electro Acupuncture in the Treatment and Management of Chemotherapy Induced Peripheral Neuropathy&quot;</brief_title>
  <official_title>&quot;Electro Acupuncture in the Treatment and Management of Chemotherapy Induced Peripheral Neuropathy&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CancerCare Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of Electro acupuncture (EA) for treatment of persistent painful
      CIPN symptoms in patients with stages 1-3 breast cancer treated with docetaxel chemotherapy 6
      months prior
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double blind prospective randomized controlled pilot study with cross over.

      To assess the effectiveness of EA in improving pain and function for chronic chemotherapy
      Induced Peripheral Neuropathy (CIPN) 30 participants will be recruited 6 months
      post-completion of chemotherapy. Fifteen participants will be randomized to the true EA group
      and 15 to the sham EA group. Those participants randomized to the sham group will cross over
      to receive true EA after the trial is complete.

      Treatment consists of EA or sham EA 1 x per week x 6 weeks. Re-assessment visits occur after
      the 6 week intervention and again 2 months post trial.

      Each assessment visit quantifies the sensory experience of CIPN at that moment in time using
      Quantitative Sensory Testing (QST) which includes; thermal detection and thermal pain
      thresholds, light touch detection using nylon monofilament hairs (Semmes Weinstein
      Monofilaments (SWMF)), static 2-point discrimination, pressure algometry and vibration
      thresholds. Patient reported outcome measures including the Disabilities of the Arm, Shoulder
      and Hand (DASH), Lower extremity functional score (LEFS), the Self report Leeds Assessment of
      Neuropathic signs and symptoms (S-LANSS) pain questionaire will also be used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>S-Lanss (short- Leads assessment of neuropathic symptoms and signs)</measure>
    <time_frame>2 years</time_frame>
    <description>16 point pain questionnaire that differentiates nociceptive from neuropathic pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS (Visual Analogue Scale)</measure>
    <time_frame>2 years</time_frame>
    <description>10 point verbal rating pain scale to measure participants pain in each assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DASH (Disabilities of the arm, shoulder, hand)</measure>
    <time_frame>2 years</time_frame>
    <description>30 item questionnaire measuring upper limb function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LEFS (Lower extremity functional scale)</measure>
    <time_frame>2 years</time_frame>
    <description>20 item questionnaire measuring lower limb function</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acupuncture will consist of acupuncture points ST36, LR3, LI4 bilaterally x 30 minutes, once a week over 6 weeks. ST36 will have EA with 2Hz at the maximum tolerated intensity (ES-130 Portable Japanese Electro-Acupuncture Device, UPC Medical Supplies Inc. South El Monte, CA, USA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Acupuncture</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham acupuncture (Streitberger Placebo Needles, Asiamed) uses the same points and treatment parameters but the placebo needle does not penetrate the skin and the current for EA is not turned on.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Acupuncture</intervention_name>
    <description>Placebo needles appear to penetrate but do not actually penetrate the skin</description>
    <arm_group_label>Sham Acupuncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient diagnosed with stage 1-3 breast cancer who has finished chemotherapy 6
             months prior and has residual CIPN symptoms graded as a 3/10 or higher on the numeric
             rating pain scale.

        Exclusion Criteria:

          -  Patients who have co-morbid conditions that cause peripheral neuropathic symptoms

          -  patients with heart valve replacements

          -  patients on prophylactic antibiotics

          -  patients with severe coagulopathy

          -  patients who did not receive regular taxane therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Shay, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Hammond, M.Sc.</last_name>
    <phone>204-451-5702</phone>
    <email>umande20@myumanitoba.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Shay, PhD</last_name>
    <phone>204-977-5636</phone>
    <email>barbara.shay@med.umanitoba.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0T6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Shay, PhD</last_name>
      <phone>204 977 5636</phone>
      <email>Barbara.Shay@med.umanitoba.ca</email>
    </contact>
    <investigator>
      <last_name>Barbara L Shay, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Barbara Shay</investigator_full_name>
    <investigator_title>Associate Professor, Department head, College of Rehabilitation Sciences</investigator_title>
  </responsible_party>
  <keyword>Electroacupuncture</keyword>
  <keyword>Neuropathic Pain</keyword>
  <keyword>Chemotherapy Induced Peripheral Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

